Skip to main navigation Skip to search Skip to main content

SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

  • Kevin Chung

Press/Media

Period9 Feb 202310 Feb 2023

Media coverage

20

Media coverage